Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending September 25, 2007. The report details a specific corporate action regarding the repurchase of the company's own ordinary shares, authorized by shareholders at the Annual General Meeting on May 23, 2007.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. The only financial data disclosed relates to the share repurchase transaction:
- Shares Purchased: 2,150,000 ordinary shares.
- Purchase Price: 1,326.2244 pence per share.
- Treasury Holdings: 408,617,158 shares (representing 7.23% of total voting rights).
- Shares in Issue: 5,617,553,219 shares (excluding Treasury shares).
Material Changes
The material change reported is the increase in the company's Treasury share holdings following the purchase of 2,150,000 shares on September 25, 2007. This transaction reduces the number of shares available for trading in the open market and adjusts the denominator for voting rights calculations.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, or discussion of risks and contingencies. It explicitly states that the announcement does not constitute an offer or solicitation to purchase securities and is made in conformity with the Transparency Directive's transitional provision 6.
Investor Verification Checklist
- Verify the total number of shares in issue (5,617,553,219) for compliance with Disclosure and Transparency Rules.
- Confirm the updated Treasury share percentage (7.23%) against the total voting rights.
- Review the authorization details from the Annual General Meeting held on May 23, 2007, to ensure the repurchase was within approved limits.